Ana Sayfa | Dergi Hakkında | Yayın Kurulu | Telif Hakkı Devir Formu | Arşiv | Yayın Arama | Yazarlara Bilgi | Etik Politikalar | İletişim  
2009, Cilt 39, Sayı 3-4, Sayfa(lar) 080-084
[ Türkçe Özet ] [ PDF ] [ Benzer Makaleler ]
ANTIMICROBIAL SUSCEPTIBILITY OF EXTENDED SPECTRUM BETA-LACTAMASE PRODUCING ESCHERICHIA COLI AND KLEBSIELLA PNEUMONIAE ISOLATES TO ERTAPENEM AND OTHER ANTIMICROBIALS
Nisel YILMAZ1, Neval AĞUŞ1, Şükran KÖSE1, Süreyya Gül YURTSEVER2, Özlem ÖNER3
1Tepecik Eğitim ve Araştırma Hastanesi İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, İzmir
2Atatürk Eğitim ve Araştırma Hastanesi Mikrobiyoloji ve Kl. Mikrobiyoloji Laboratuvarı, İzmir
3EÜ Fen Fakültesi Biyoloji Bölümü, Temel ve Endüstriyel Mikrobiyoloji AD, İzmir
Keywords: Ertapenem, extended spectrum beta-lactamase (ESBL), Escherichia coli, Klebsiella pneumoniae

Infections caused by multiply drug resistant organisms such as extended spectrum beta-lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae are increasing. Carbapenems (imipenem ve meropenem) are the antibiotics commonly used to treat these agents. Th e aim of this paper to determine the in-vitro activity of ertapenem, which is the newest carbapenem, for ESBL-producing E. coli ve K. pneumoniae isolates.

Th e bacteria were identified by conventional methods and Vitek-2 automated system. Th e antimicrobial susceptibility of antibiotics were tested by Kirby-Bauer disk diff usion method according to CLSI criteria. ESBL production were detected using cefotaxim/cefotaxim-clavulanate disks.

A total of 390 isolates (300 E. coli, 90 K. pneumoniae) were studied. Ertapenem resistance was detected in 10 E. coli (%3) and 12 K. pneumoniae (%13) strains. Two of E. coli and four of K. pneumoniae strains were also resistant to imipenem. Amikacin was the most susceptible agents for ESBL-producing isolates aft er carbapenem. High resistant rate to ciprofloksasin and trimethoprim-sulfamethoxazole were observed.

Ertapenem showed high in-vitro activity against E. coli and K. pneumoniae isolates. Th ese results suggest that ertapenem may be an good alternative for the treatment of infections caused by ESBL-producing isolates.


[ Türkçe Özet ] [ PDF ] [ Benzer Makaleler ]
Ana Sayfa | Dergi Hakkında | Yayın Kurulu | Telif Hakkı Devir Formu | Arşiv | Yayın Arama | Yazarlara Bilgi | Etik Politikalar | İletişim